Prognostic value of p53 overexpression in bladder tumors treated with Bacillus Calmette-Guerin

References

• Finlay CA, Hinds PW, Levine AJ. The p53 proto-oncogene can act as a suppressor of transformation. Ce1157 (7), 1083–1093 (1989).
   Google Scholar
• Carson DA, Lois A. Cancer progression and p53. Lancet 346(8981), 1009–1011 (1995).
   Google Scholar
• Levine AJ, Momand J, Finlay CA. The p53 tumour suppressor gene. Nature 351(6326), 453–456 (1991).
   Google Scholar
• Cordon-Cardo C, Dalbagni G, Saez GT et al. p53 mutations in human bladder cancer: genotypic versusphenotypic patterns. Int. I Cancer56(3), 347–353 (1994).
   Google Scholar
• Esrig D, Spruck CH, Nichols PW et al. p53 nuclear protein accumulation correlates with mutations in the p53 gene, tumor grade and stage in bladder cancer. Am. J. Pathol 143(5), 1389–1397 (1993).
   Google Scholar
• Sarkis AS, Dalbagni G, Cordon-Cardo C et al. Nuclear overexpression of p53 protein in transitional cell bladder carcinoma: a marker for disease progression. J. Natl Cancer Ins& 85(1), 53–58 (1993).
   Google Scholar
• Serth J, Kuczyk MA, Bokemeyer C et al. p53 immunohistochemistry as an independent prognostic factor for superficial transitional cell carcinoma of the bladder. Br Cancer71 (1), 201–205 (1995).
   Google Scholar
• Schmitz-Drager BJ, Kushima M, Goebell P et al. p53 and MDM2 in the development and progression of bladder cancer. Eur. Urol. 32(4), 487–493 (1997).
   Google Scholar
• Wu TT, Chen JH, Lee YH, Huang JK. The role of BCL-2, p53 and KI-67 in predicting tumor recurrence for low grade superficial transitional cell bladder carcinoma. j Urol. 163(3), 758–760 (2000).
   Google Scholar
• Shariat SF, Weizer AZ, Green A, Laucirica R, Frolov A, Wheeler TM. Prognostic value of p53 nuclear accumulation and histopathologic features in Ti transitional cell carcinoma of the urinary bladder. Urology 56 (5), 735–740 (2000).
   Google Scholar
• Bernardini S, Billerey C, Martin M, Adessi GL, Wallerand H, Bittard H. The predictive value of muscularis mucosae invasion and p53 overexpression on progression of stage Ti bladder carcinoma. J. Urol. 165(1), 42–46 (2001).
   Google Scholar
• Tsuji M, Kojima K, Murakami Y, Kanayama H, Kagawa S. Prognostic value of Ki-67 antigen and p53 protein in urinary badder cancer: immunohistochemical analysis of radical cystectomy specimens. Bcj Urol 79(3), 367–372 (1997).
   Google Scholar
• Johnson S, Karlsson MG. Predictive value of p53 and pRb immunostaining in locally advanced bladder cancer treated with cystectomy. Urol. 160(4), 1291–1296 (1998).
   Google Scholar
• Bernardini S, Chabannes E, Bittard H. Usefulness of p53 in the clinical management of bladder cancer. Frog. Urol 11(2), 201–208 (2001).
   Google Scholar
• Baas TO, Mulder JW, Offerhaus GJ, Vogelstein B, Hamilton SR An evaluation of six antibodies for immunochemistry of mutant p53 gene product in archival colorectal neoplasms. J. Pathol 172(1), 5–12 (1994).
   Google Scholar
• Bernardini S, Adessi GL, Billerey C, Chezy E, Carbillet JP, Bittard H. Immunohistochemical detection of p53 protein overexpression versus gene sequencing in urinary bladder carcinomas . I Urol. 162 (4), 1496–1501 (1999).
   Google Scholar
• Pansadoro V, Emiliozzi P, de Paula F, Scarpone P, Pansadoro A, Sternberg CN. Long-term follow-up of G3T1 transitional cell carcinoma of the bladder treated with intravesical bacille Calmette-Guerin: 18 year-experience. Urology 59 (2), 227–231 (2002).
   Google Scholar
• Appleman LJ, Frey AB. Dominant-negative p53 can restore tumorigenicity of L-929 cells in immunocompetent mice. Lit J. Cancer63(4), 576–583 (1995).
   Google Scholar
• Hudson MA, Nadler RB, Swanson PE et al. p53 protein accumulation in superficial bladder cancer: a predictor of tumor progression which is not affected by intravesical BCG therapy. J. Urol. 153, A361 (1995) (Abstract).
   Google Scholar
• Caliskan M, Tarkeri LN, Mansuroglu B et al. Nuclear accumulation of mutant p53 protein: a possible predictor of failure of intravesical therapy in bladder cancer. Br J. Urol. 79(3), 373–377 (1997).
   Google Scholar
• Lee E, Park I, Lee C. Prognostic markers of intravesical bacillus Calmette-Guerin therapy for multiple, high-grade, stage Ti bladder cancers. hit.j Urol 4(6), 552–556 (1997).
   Google Scholar
• Lacombe L, Dalbagni G, Zhang ZK et al. Overexpression of p53 protein in high-risk population of patients with superficial cancer before and after bacillus Calmette-Guerin therapy: correlation to clinical outcome.j Clin. Oncol 14(10), 2646–2652 (1996).
   Google Scholar
• Zlotta AR, Noel JC, Fayt 1 et al. Correlation and prognostic significance of P53, p21 and Ki-67 expression in patients with superficial bladder tumors treated with bacillus Calmette-Guerin intravesical therapy.j Urol. 161(3), 792–798 (1999).
   Google Scholar
• Pages F, Ham TA, Vieillefond A et al. p53 status does not predict initial clinical response to bacillus Calmette-Guerin intravesical therapy in Ti bladder tumors. Uml 159(3), 1079–1084 (1998).
   Google Scholar
• Lebret T, Becette V, Barbagelatta et al. Correlation between p53 overexpression and response to bacillus Calmette-Guerin therapy in a high risk select population of patients with T1G3 bladder cancer. j Urol 159(3), 788–791 (1998).
   Google Scholar
• Peyromaure M, Weibing S, Sebe P et al. Prognostic value of p53 overexpression in Ti G3 bladder tumors treated with bacillus Calmette-Guerin therapy. Urology59 (3), 409–413 (2002).
   Google Scholar
• Ovesen H, Horn T, Steven K. Long-term efficacy of intravesical bacillus Calmette-Guerin for carcinoma in situ: relationship of progression to histological response and p53 nuclear accumulation. J. Uml 157(5), 1655–1659 (1997).
   Google Scholar
• Ick K, Schultz M, Stout P et al. Significance of p53 overexpression in urinary bladder transitional cell carcinoma in situ before and after bacillus Calmette-Guerin treatment. Urology49(4), 541–546 (1997).
   Google Scholar
• Dalbagni G, Lacombe L, Fair WR, Herr HW, Reuter VE. Evaluation of p53 expression in superficial bladder tumors before and after BCG and comparison to clinical outcome. Urol. 153, A363 (1995) (Abstract). Affiliations
   Google Scholar